Cryoablation with or Without Serplulimab in Treating Patients with Stage I-IIA Non-small Cell Lung Cancer

NCT ID: NCT06580665

Last Updated: 2024-08-30

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: NA
• Total Enrollment: 134 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-09-01
• Study Completion Date: 2030-08-11

Brief Summary

Cryoablation is a minimally invasive technique that utilizes very low temperature to eliminate tumour cells for patients ineligible for surgery. It has been reported that cryoablation may enhance immune response and synergize with immunotherapy.

This study is a multicenter, randomized, controlled, exploratory trial, and is expected to enroll a total of 134 patients. The enrolled patients were stage Ia, Ib, or IIa lung cancer with negative driver gene mutations, who are considered high-risk for surgery or refuse surgery based on multidisciplinary evaluation. Eligible patients will be randomly assigned in a 1:1 ratio to receive either cryoablation alone (CA group) or cryoablation combined with immunotherapy (I-CA group). The study aims to evaluate the safety and clinical benefits of combining immunotherapy with cryoablation in the treatment of early-stage NSCLC by comparing progression-free survival (PFS), objective response rate (ORR), overall survival (OS), and the incidence of adverse events between the two groups.

Conditions

Non-small Cell Lung Cancer

Keywords

Cryoablation; Serplulimab; Early non-small cell lung cancer

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: SINGLE

Study Groups

Cryoablation alone (CA group)

Patients undergo cryoablation alone.

Group Type: EXPERIMENTAL

Cryoablation

Intervention Type: PROCEDURE

Patients undergo cryoablation.

Cryoablation combined with immunotherapy (I-CA group)

Patients undergo cryoablation. If there are no significant postoperative complications, Serplulimab should be administered immediately. Cycles with Serplulimab repeat every 3 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity.

Group Type: EXPERIMENTAL

Cryoablation

Intervention Type: PROCEDURE

Patients undergo cryoablation.

Serplulimab

Intervention Type: DRUG

Patients undergo cryoablation. If there are no significant postoperative complications, Serplulimab should be administered immediately. Cycles with Serplulimab repeat every 3 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity.

Interventions

Cryoablation

Patients undergo cryoablation.

Intervention Type: PROCEDURE

Serplulimab

Patients undergo cryoablation. If there are no significant postoperative complications, Serplulimab should be administered immediately. Cycles with Serplulimab repeat every 3 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Pathologically diagnosed as primary peripheral non-small cell lung cancer, preoperative staging suggested stage Ia, Ib, or IIa (size≤5 cm, T1-T2N0M0), according to the 9th edition of the TNM classification for lung cancer;

2. Negative driver gene mutation: driver genes were defined as EGFR, ALK, etc;

3. Age ≥18 years old;

4. The ECOG PS score is 0-2;

5. Expected survival ≥3 months;

6. Patients who are considered high-risk for surgery/radiotherapy or refuse surgery/radiotherapy based on multidisciplinary evaluation;

7. Patients who have not received previous immunotherapy with PD-1, PD-L1 or CTLA-4 antibodies;

8. All patients must agree to receive cryoablation (with or without Serplulimab) as an initial therapy and sign a study-specific consent form.

Exclusion Criteria

1. Patients with poor cardiopulmonary function or other comorbidities who cannot tolerate multimode thermal therapy;

2. Patients whose chest CT indicated that the lung lesions could not be reached percutaneously or transbronchially;

3. Severe liver and kidney function and coagulation function abnormalities, platelet count <70×109/L;

4. Patients who have received other anti-tumor drugs in the past 6 months or have used immune checkpoint inhibitors before;

5. The patient has an uncontrolled disease (including but not limited to active infection, symptomatic congestive heart failure, unstable angina, arrhythmia, mental illness, etc.);

6. Primary immune deficiency or autoimmune diseases (e.g. rheumatoid arthritis, systemic lupus erythematosus, etc.);

7. Pregnant and lactating women;

8. Long-term use of steroid;

9. Other circumstances considered inappropriate for participation in this study.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Shanghai Henlius Biotech Co., Ltd.

UNKNOWN

Sponsor Role: collaborator

AccuTarget MediPharma (Shanghai) Co., Ltd

UNKNOWN

Sponsor Role: collaborator

Shanghai Chest Hospital

OTHER

Sponsor Role: lead

Responsible Party

Jiayuan Sun

Director, Department of Respiratory Endoscopy

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

Wuhan, Hubei, China

The First Affiliated Hospital of Nanchang University

Nanchang, Jiangxi, China

Shanghai Chest Hospital

Shanghai, Shanghai Municipality, China

The First Affiliated Hospital of Xinjiang Medical University

Ürümqi, Xinjiang, China

The First Affiliated Hospital of Wenzhou Medical University

Wenzhou, Zhejiang, China

Countries

China

Central Contacts

Jiayuan Sun

Role: CONTACT

Phone: +86-021-22200000

Email: jysun1976@163.com

Other Identifiers

IS24040

Identifier Type: -

Identifier Source: org_study_id